CoChat

RKIP Contributes to IFN-γ Synthesis by CD8+ T Cells after Serial TCR Triggering in Systemic Inflammatory Response Syndrome

Wright, Kyle T, Vella, Anthony T · 2013 · The Journal of Immunology
Cited by 27

The DOI matches its Crossref record.

Abstract

Systemic inflammatory response syndrome (SIRS) is associated with the development of severe medical complications, including progression to multiple organ dysfunction syndrome and even death. To date, only marginal improvements in terms of therapeutic options have been established for patients affected by SIRS. Raf kinase inhibitor protein (RKIP) is a regulator of MAPK and NF-κB signaling cascades, which are both critical for production of the proinflammatory cytokines responsible for SIRS initiation. By testing a T cell–dependent mouse model of SIRS that utilizes staphylococcal enterotoxin A specific for Vβ3+ T cells, we show that RKIP is necessary for the exaggerated production of IFN-γ from SIRS splenocytes. This effect was not due to differences in T cell expansion, IL-10 production, or APC priming, but rather a cell-intrinsic defect lying downstream of the TCR in staphylococcal enterotoxin A–specific CD8+ T cells. Importantly, mice lacking RKIP were still able to proliferate, survive, and contribute to cytokine production in response to pathogen associated molecular pattern-TLR–mediated stimuli, despite the TCR-dependent defects seen in our SIRS model. Finally, by blocking RKIP in wild-type SIRS splenocytes, the IFN-γ response by CD8+ Vβ3+ T cells was significantly diminished. These data suggest that RKIP may be a potential therapeutic target in SIRS by curbing effector cytokine production from CD8+ T cells during serial TCR triggering.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1203486

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 51

  1. Bone, 1992, Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome), JAMA, 268, 3452, 10.1001/jama.1992.03490240060037 · DOI · Paper page
  2. Hotchkiss, 2003, The pathophysiology and treatment of sepsis, N. Engl. J. Med., 348, 138, 10.1056/NEJMra021333 · DOI · Paper page
  3. Rangel-Frausto, 1995, The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study, JAMA, 273, 117, 10.1001/jama.1995.03520260039030 · DOI · Paper page
  4. Neviere, 2012, UpToDate
  5. Angus, 2001, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care, Crit. Care Med., 29, 1303, 10.1097/00003246-200107000-00002 · DOI · Paper page
  6. Abraham, 1998, Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock, Lancet, 351, 929, 10.1016/S0140-6736(05)60602-2 · doi:10.1016/s0140-6736(05)60602-2 · Paper page
  7. Abraham, 1995, Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial: TNF-alpha MAb Sepsis Study Group, JAMA, 273, 934, 10.1001/jama.1995.03520360048038 · DOI · Paper page
  8. Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein, N. Engl. J. Med., 334, 1697, 10.1056/NEJM199606273342603 · DOI · Paper page
  9. Opal, 1997, Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial: The Interleukin-1 Receptor Antagonist Sepsis Investigator Group, Crit. Care Med., 25, 1115, 10.1097/00003246-199707000-00010 · DOI · Paper page
  10. Russell, 2006, Management of sepsis, N. Engl. J. Med., 355, 1699, 10.1056/NEJMra043632 · DOI · Paper page
  11. Annane, 2009, Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review, JAMA, 301, 2362, 10.1001/jama.2009.815 · DOI · Paper page
  12. Todd, 1978, Toxic-shock syndrome associated with phage-group-I Staphylococci, Lancet, 2, 1116, 10.1016/S0140-6736(78)92274-2 · DOI · Paper page
  13. Kappler, 1992, Mutations defining functional regions of the superantigen staphylococcal enterotoxin B, J. Exp. Med., 175, 387, 10.1084/jem.175.2.387 · DOI
  14. McCormick, 2001, Toxic shock syndrome and bacterial superantigens: an update, Annu. Rev. Microbiol., 55, 77, 10.1146/annurev.micro.55.1.77 · DOI · Paper page
  15. Pontzer, 1992, T-cell antigen receptor binding sites for the microbial superantigen staphylococcal enterotoxin A, Proc. Natl. Acad. Sci. USA, 89, 7727, 10.1073/pnas.89.16.7727 · doi:10.1073/pnas.89.16.7727
  16. Muralimohan, 2008, Inhalation of Staphylococcus aureus enterotoxin A induces IFN-gamma and CD8 T cell-dependent airway and interstitial lung pathology in mice, J. Immunol., 181, 3698, 10.4049/jimmunol.181.5.3698 · DOI
  17. Ménoret, 2012, Cytochrome b5 and cytokeratin 17 are biomarkers in bronchoalveolar fluid signifying onset of acute lung injury, PLoS One, 7, e40184, 10.1371/journal.pone.0040184 · doi:10.1371/journal.pone.0040184
  18. Rajagopalan, 2006, Intranasal exposure to staphylococcal enterotoxin B elicits an acute systemic inflammatory response, Shock, 25, 647, 10.1097/01.shk.0000209565.92445.7d · DOI
  19. Ward, 2008, The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients, Clin. Chest Med., 29, 617, 10.1016/j.ccm.2008.06.010 · DOI · Paper page
  20. Cauley, 1997, Transferable anergy: superantigen treatment induces CD4+ T cell tolerance that is reversible and requires CD4−CD8− cells and interferon gamma, J. Exp. Med., 186, 71, 10.1084/jem.186.1.71 · DOI
  21. Vallabhapurapu, 2009, Regulation and function of NF-kappaB transcription factors in the immune system, Annu. Rev. Immunol., 27, 693, 10.1146/annurev.immunol.021908.132641 · DOI · Paper page
  22. Chang, 2001, Mammalian MAP kinase signalling cascades, Nature, 410, 37, 10.1038/35065000 · DOI · Paper page
  23. Yeung, 1999, Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP, Nature, 401, 173, 10.1038/43686 · DOI · Paper page
  24. Yeung, 2001, Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation, Mol. Cell. Biol., 21, 7207, 10.1128/MCB.21.21.7207-7217.2001 · DOI · Paper page
  25. Yeung, 2000, Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein, Mol. Cell. Biol., 20, 3079, 10.1128/MCB.20.9.3079-3085.2000 · DOI · Paper page
  26. Tang, 2010, RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex, FEBS Lett., 584, 662, 10.1016/j.febslet.2009.12.051 · DOI
  27. Fu, 2003, Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis, J. Natl. Cancer Inst., 95, 878, 10.1093/jnci/95.12.878 · DOI · Paper page
  28. Hagan, 2005, Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis, Clin. Cancer Res., 11, 7392, 10.1158/1078-0432.CCR-05-0283 · DOI · Paper page
  29. Beshir, 2011, Locostatin disrupts association of Raf kinase inhibitor protein with binding proteins by modifying a conserved histidine residue in the ligand-binding pocket, For. Immunopathol. Dis. Therap., 2, 47
  30. Theroux, 2007, Raf kinase inhibitory protein knockout mice: expression in the brain and olfaction deficit, Brain Res. Bull., 71, 559, 10.1016/j.brainresbull.2006.11.010 · DOI
  31. Nagy, 2003, Manipulating the Mouse Embryo: A Laboratory Manual
  32. McAleer, 2010, Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization, J. Leukoc. Biol., 88, 21, 10.1189/jlb.0909631 · DOI
  33. McAleer, 2007, The lipopolysaccharide adjuvant effect on T cells relies on nonoverlapping contributions from the MyD88 pathway and CD11c+ cells, J. Immunol., 179, 6524, 10.4049/jimmunol.179.10.6524 · DOI
  34. Unkeless, 1979, Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors, J. Exp. Med., 150, 580, 10.1084/jem.150.3.580 · DOI · Paper page
  35. McCormack, 1993, Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen, J. Immunol., 150, 3785, 10.4049/jimmunol.150.9.3785 · DOI · Paper page
  36. Selberg, 2000, Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6, Crit. Care Med., 28, 2793, 10.1097/00003246-200008000-00019 · DOI · Paper page
  37. Rodríguez-Gaspar, 2001, Prognostic value of cytokines in SIRS general medical patients, Cytokine, 15, 232, 10.1006/cyto.2001.0932 · DOI
  38. Zhang, 2005, Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition, J. Immunol., 174, 8125, 10.4049/jimmunol.174.12.8125 · DOI · Paper page
  39. Zein, 2004, Prognostic significance of elevated serum lactate dehydrogenase (LDH) in patients with severe sepsis, Chest, 126, S873, 10.1378/chest.126.4_MeetingAbstracts.873S · doi:10.1378/chest.126.4_meetingabstracts.873s
  40. Moore, 2001, Interleukin-10 and the interleukin-10 receptor, Annu. Rev. Immunol., 19, 683, 10.1146/annurev.immunol.19.1.683 · DOI · Paper page
  41. Florquin, 1994, Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice, J. Immunol., 153, 2618, 10.4049/jimmunol.153.6.2618 · DOI
  42. O’Garra, 2004, IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage, J. Clin. Invest., 114, 1372, 10.1172/JCI23215 · doi:10.1172/jci23215 · Paper page
  43. Herman, 1991, Superantigens: mechanism of T-cell stimulation and role in immune responses, Annu. Rev. Immunol., 9, 745, 10.1146/annurev.iy.09.040191.003525 · doi:10.1146/annurev.iy.09.040191.003525 · Paper page
  44. Seok, 2013, Genomic responses in mouse models poorly mimic human inflammatory diseases, Proc. Natl. Acad. Sci. USA, 110, 3507, 10.1073/pnas.1222878110 · DOI · Paper page
  45. Mueller, 1989, Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy, Annu. Rev. Immunol., 7, 445, 10.1146/annurev.iy.07.040189.002305 · DOI · Paper page
  46. Fry, 2012, Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues, Am. Surg., 78, 1, 10.1177/000313481207800102 · DOI · Paper page
  47. Annane, 2002, Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock, JAMA, 288, 862, 10.1001/jama.288.7.862 · DOI · Paper page
  48. Schuierer, 2006, Induction of Raf kinase inhibitor protein contributes to macrophage differentiation, Biochem. Biophys. Res. Commun., 342, 1083, 10.1016/j.bbrc.2006.02.083 · DOI
  49. Zhu, 2005, A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration, Chem. Biol., 12, 981, 10.1016/j.chembiol.2005.07.007 · DOI
  50. Ménoret, 2009, The oxazolidinone derivative locostatin induces cytokine appeasement, J. Immunol., 183, 7489, 10.4049/jimmunol.0901414 · doi:10.4049/jimmunol.0901414
  51. Shemon, 2009, Raf kinase inhibitory protein protects cells against locostatin-mediated inhibition of migration, PLoS One, 4, e6028, 10.1371/journal.pone.0006028 · doi:10.1371/journal.pone.0006028

Cited by

See all 27

Metadata

Authors
Wright, K. T., & Vella, A. T.
Affiliations
Department of Immunology, University of Connecticut Health Center , Farmington, CT 06030
Venue
The Journal of Immunology
Published
2013-07
Volume
191
Issue
2
Pages
708-716
ISSN
  • 0022-1767
  • 1550-6606
Cited by
27
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RKIP Contributes to IFN-γ Synthesis by CD8+ T Cells after Serial TCR Triggering in Systemic Inflammatory Response Syndrome. https://app.cochat.ai/papers/10.4049/jimmunol.1203486
The paper
Wright, K. T., & Vella, A. T. (2013). RKIP Contributes to IFN-γ Synthesis by CD8+ T Cells after Serial TCR Triggering in Systemic Inflammatory Response Syndrome. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1203486

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.